ArmonAir™ RespiClick® (fluticasone) – New drug approval
January 30, 2017 – Teva announced the FDA approval of ArmonAir RespiClick (fluticasone), for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Download PDF
